FDA Announces Public Advisory Committee Meeting on Immune Checkpoint Inhibitors for Certain Cancers

Summary

The FDA is hosting a public meeting of its Oncologic Drugs Advisory Committee to discuss the use of immune checkpoint inhibitors in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma, and is seeking public comments on the topic.